pasireotide

Known as: Pasireotida, Cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L-phenylalanyl-), cyclo((4R)-4-(2-Aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-) 
A synthetic long-acting cyclic peptide with somatostatin-like activity. Pasireotide activates a broad spectrum of somatostatin receptors, exhibiting… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2018
0204020062018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
UNLABELLED Malignant insulinoma usually has a poor prognosis, as no efficient medical treatment is available. The somatostatin… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Postoperative pancreatic fistula is a major contributor to complications and death associated with pancreatic… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
CONTEXT Biochemical control reduces morbidity and increases life expectancy in patients with acromegaly. With current medical… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
CONTEXT Pasireotide (SOM230) is a somatostatin analog with affinity for somatostatin receptor subtypes sst₁₋₃ and sst₅. Clinical… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Cushing's disease is associated with high morbidity and mortality. Pasireotide, a potential therapy, has a unique… (More)
  • table 1
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2012
2012
Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
CONTEXT Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for somatostatin receptor subtypes… (More)
Is this relevant?
2010
2010
Pasireotide (SOM230) is currently under clinical evaluation as a successor compound to octreotide for the treatment of acromegaly… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
CONTEXT There is currently no medical therapy for Cushing's disease that targets the pituitary adenoma. Availability of such a… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2009
2009
OBJECTIVE The clinically used somatostatin analogs, octreotide and lanreotide, act primarily by binding to somatostatin receptor… (More)
Is this relevant?